The Center for Blood and Cancer Disorders in Fort Worth, Texas, is participating in many value-based contracts. Here’s how it is successful.
Ron Barkley, president of the Cancer Center Business Development Group, which consults with oncology providers on value-based care arrangements, shares tips.
To get a pulse on the U.S.
Douglas Long, vice president of industry relations at Durham, NC-based IQVIA, a newly named company after the merger of IMS Health and Quintiles, discussed pharmaceutical marketplace trends during the headline session at the Academy of Ma
Payers are stepping up efforts to manage the cost and utilization of orphan drug treatments.
The cost to treat cancer in the United States could reach $156 billion in 2020, according to the National Cancer Institute. And innovative medications have a significant impact on the cost of care.
Gene therapy, which got its start in the 1960s, is finally starting to take hold.
Expiring patents and biosimilar developments are creating big market opportunities within the specialty drug space.
High-cost treatments for rheumatoid arthritis has fueled the need to better understand their value to healthcare systems and patients.
CEO of a Pennsylvania-based oncology group shares how participating in a new value-based model is changing the care approach.